Clinical Trial Design in Alzheimer's Disease
Our understanding of Alzheimer's disease (AD) has drastically improved during the past decade as multiple large-scale studies have been implemented. These studies try to provide a large data set of markers and characteristics of patients with AD. The complexity of these factors and the disease itself have hindered the introduction of novel therapeutic strategies for patients with AD and the success rate of clinical trials in AD is significantly low.
We propose the idea of implementing future clinical trials in AD in a more specified population of AD patients based on the mechanism of action of the drug candidate, stage of the disease, and markers involved in the pathogenesis and severity of the disease. The derived results of such trials will not have the problems of doing a post hoc analysis, and although it may harm the generalizability of the results, we may find novel and effective treatment approaches for AD patients with similar characteristics.
2. Solomon A, Kivipelto M, Molinuevo JL, Tom B, Ritchie CW, Consortium E. European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open 2019;8(12):e021017.
3. Weiner MW, Veitch DP, Aisen PS, et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 2015;11(7):865-84.
4. Liyanage SI, Santos C, Weaver DF. The hidden variables problem in Alzheimer's disease clinical trial design. Alzheimers Dement (NY) 2018;4:628-35.
5. Viggars AP, Wharton SB, Simpson JE, et al. Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort. Neurosci Lett 2011;505(1):25-30.
6. Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin Transl Sci 2018;11(2):147-52.
7. Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines 2019;7(4).
|Issue||Vol 10, No 2 (Spring 2022)|
|Alzheimer's Disease Clinical Trial Design|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|